The recent development of ²²⁵Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters ²²⁵Actinium and its daughter nuclide ²¹³Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with ²²⁵Ac or ²¹³Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
No takes yet. Share an insight, caveat, or question.
Morgenstern et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: